小核酸领域再迎重磅BD(商务拓展)交易。 2月23日晚间,科创板创新药企前沿生物(688221.SH)公告,已与葛兰素史克(GSK)达成一项独家授权许可协议,GSK获得公司两款小核酸(siRNA)管线产品在全球范围内的独家开发、生产及商业化权利。 协议显示,其中一款候选药物已进入新药临床试验申请(IND)阶段,另一款为临床前候选药物。前沿生物将负责其中一款产品在中国的I期临床试验推进,并完成另...
Source Link小核酸领域再迎重磅BD(商务拓展)交易。 2月23日晚间,科创板创新药企前沿生物(688221.SH)公告,已与葛兰素史克(GSK)达成一项独家授权许可协议,GSK获得公司两款小核酸(siRNA)管线产品在全球范围内的独家开发、生产及商业化权利。 协议显示,其中一款候选药物已进入新药临床试验申请(IND)阶段,另一款为临床前候选药物。前沿生物将负责其中一款产品在中国的I期临床试验推进,并完成另...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.